Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach

被引:26
作者
Packeu, A. [1 ]
Wennerberg, M. [2 ]
Balendran, A. [2 ]
Vauquelin, G. [1 ]
机构
[1] Free Univ Brussels VUB, Dept Mol & Biochem Pharmacol, B-1050 Brussels, Belgium
[2] AstraZeneca R&D, Molndal, Sweden
关键词
radioligand binding; dissociation; kinetics; D-2; dopamine; CB1; cannabinoid; membrane partitioning; computer simulations; AT(1) RECEPTOR; PHARMACOLOGICAL CHARACTERIZATION; ATYPICAL ANTIPSYCHOTICS; RADIOLIGAND BINDING; TYPE-1; RECEPTOR; RESIDENCE TIME; ANTAGONIST; DRUG; MECHANISMS; DOPAMINE;
D O I
10.1111/j.1476-5381.2010.00931.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND AND PURPOSE Because the in vivo effectiveness of ligands may also be determined by the rate by which they dissociate from their target receptors, drug candidates are being increasingly screened for this kinetic property. The dissociation rate of unlabelled ligand-receptor complexes can be estimated indirectly from their ability to slow the association of subsequently added radioligand molecules. EXPERIMENTAL APPROACH We used the 'two-step competition' binding approach consisting of pre-incubating the receptor preparation with a wide range of ligand concentrations, washing off free ligand molecules, adding radioligand and monitoring its receptor binding after a fixed time. Based on the rationale that binding of both ligands is mutually exclusive and that they bind according to the law of mass action to a single class of sites, the unlabelled ligand's disociation rate can be estimated from the upward shift that the competition curve experiences after washing. KEY RESULTS The relevance of the 'two-step competition' approach was explored by computer simulations and by comparing the dissociation behaviour of unlabelled D-2 dopamine and CB1 cannabinoid receptor antagonists in this and alternative approaches. Besides providing satisfactory estimations of dissociation rates, the method also detects the ability of the unlabelled ligand molecules to be released from 'sinks' such as the cell membrane. CONCLUSIONS AND IMPLICATIONS As the 'two-step competition' requires rapid intermediate washing steps and needs radioligand binding to be measured at only one time point, this approach is particularly suited for binding studies on intact plated cells. LINKED ARTICLES This article is part of a themed section on Analytical Receptor Pharmacology in Drug Discovery. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2010.161.issue-6.
引用
收藏
页码:1311 / 1328
页数:18
相关论文
共 53 条
[1]   PHARMACOLOGY OF A POTENT LONG-ACTING IMIDAZOLE-5-ACRYLIC ACID ANGIOTENSIN AT(1) RECEPTOR ANTAGONIST [J].
AIYAR, N ;
BAKER, E ;
VICKERYCLARK, L ;
OHLSTEIN, EH ;
GELLAI, M ;
FREDRICKSON, TA ;
BROOKS, DP ;
WEINSTOCK, J ;
WEIDLEY, EF ;
EDWARDS, RM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 283 (1-3) :63-72
[2]  
Alexander SPH, 2009, BRIT J PHARMACOL, V158, pS1, DOI 10.1111/j.1476-5381.2009.00499.x
[3]   WHY ARE LONG-ACTING BETA-ADRENOCEPTOR AGONISTS LONG-ACTING [J].
ANDERSON, GP ;
LINDEN, A ;
RABE, KF .
EUROPEAN RESPIRATORY JOURNAL, 1994, 7 (03) :569-578
[4]   FORMOTEROL - PHARMACOLOGY, MOLECULAR-BASIS OF AGONISM, AND MECHANISM OF LONG-DURATION OF A HIGHLY POTENT AND SELECTIVE BETA(2)-ADRENOCEPTOR AGONIST BRONCHODILATOR [J].
ANDERSON, GP .
LIFE SCIENCES, 1993, 52 (26) :2145-2160
[5]   Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1 receptor [J].
Anthes, JC ;
Gilchrest, H ;
Richard, C ;
Eckel, S ;
Hesk, D ;
West, RE ;
Williams, SM ;
Greenfeder, S ;
Billah, M ;
Kreutner, W ;
Egan, RW .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 449 (03) :229-237
[6]   QSAR and the rational design of long-acting dual D2-receptor/β2-adrenoceptor agonists [J].
Austin, RP ;
Barton, P ;
Bonnert, RV ;
Brown, RC ;
Cage, PA ;
Cheshire, DR ;
Davis, AM ;
Dougall, IG ;
Ince, F ;
Pairaudeau, G ;
Young, A .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (15) :3210-3220
[7]   Extent of salmeterol-mediated reassertion of relaxation in guineapig trachea pretreated with aliphatic side chain structural analogues [J].
Bergendal, A ;
Linden, A ;
Skoogh, BE ;
Gerspacher, M ;
Anderson, GP ;
Lofdahl, CG .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 117 (06) :1009-1015
[8]   Granisetron: relating pharmacology to clinical efficacy [J].
Blower, PR .
SUPPORTIVE CARE IN CANCER, 2003, 11 (02) :93-100
[9]   Exosites: Their current status, and their relevance to the duration of action of long-acting beta(2)-adrenoceptor agonists [J].
Coleman, RA ;
Johnson, M ;
Nials, AT ;
Vardey, CJ .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1996, 17 (09) :324-330
[10]   Opinion - Drug-target residence time and its implications for lead optimization [J].
Copeland, Robert A. ;
Pompliano, David L. ;
Meek, Thomas D. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :730-739